Huitema ADR - Search Results

1

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Among authors: huitema adr. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.

2

Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.

van der Schoot SC, Nuijen B, Huitema AD, Beijnen JH. van der Schoot SC, et al. Pharm Res. 2007 Mar;24(3):605-12. doi: 10.1007/s11095-006-9179-y. Pharm Res. 2007. PMID: 17245647 Free PMC article.

3

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, Schellens JH, Beijnen JH. Lankheet AG, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3625-30. doi: 10.1016/j.jchromb.2009.09.001. Epub 2009 Sep 6. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19762293

4

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH, Nuijen B. Moes JJ, et al. Int J Pharm. 2011 Nov 28;420(2):244-50. doi: 10.1016/j.ijpharm.2011.08.041. Epub 2011 Sep 2. Int J Pharm. 2011. PMID: 21907780 Clinical Trial.

5

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH. Joerger M, et al. Cancer. 2012 May 1;118(9):2466-75. doi: 10.1002/cncr.26562. Epub 2011 Sep 28. Cancer. 2012. PMID: 22031394 Free article. Clinical Trial.

6

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH. Devriese LA, et al. Br J Clin Pharmacol. 2013 Feb;75(2):507-15. doi: 10.1111/j.1365-2125.2012.04381.x. Br J Clin Pharmacol. 2013. PMID: 22803519 Free PMC article.

7

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Moes J, et al. Eur J Pharm Biopharm. 2013 Jan;83(1):87-94. doi: 10.1016/j.ejpb.2012.09.016. Epub 2012 Oct 17. Eur J Pharm Biopharm. 2013. PMID: 23085332 Clinical Trial.

8

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. Leijen S, et al. Gynecol Oncol. 2013 Sep;130(3):511-7. doi: 10.1016/j.ygyno.2013.05.001. Epub 2013 May 9. Gynecol Oncol. 2013. PMID: 23665458 Clinical Trial.

9

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, Voest EE, Schellens JH. Stuurman FE, et al. J Clin Pharmacol. 2013 Aug;53(8):878-83. doi: 10.1002/jcph.108. Epub 2013 Jun 18. J Clin Pharmacol. 2013. PMID: 23775853 Clinical Trial. No abstract available.

10

Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.

Meulenaar J, Keizer RJ, Beijnen JH, Schellens JH, Huitema AD, Nuijen B. Meulenaar J, et al. J Pharm Sci. 2014 Feb;103(2):478-84. doi: 10.1002/jps.23779. Epub 2013 Dec 5. J Pharm Sci. 2014. PMID: 24311366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

540 results

Search Page

Filters